17,077 Shares in Bristol Myers Squibb Company $BMY Purchased by Avaii Wealth Management LLC

Avaii Wealth Management LLC purchased a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor purchased 17,077 shares of the biopharmaceutical company's stock, valued at approximately $984,000.

• 2 Buffett Stocks to Load Up On—And 1 to Ditch

Several other institutional investors have also added to or reduced their stakes in BMY. Swiss RE Ltd. purchased a new position in shares of Bristol Myers Squibb during the fourth quarter valued at approximately $25,000. Darwin Wealth Management LLC purchased a new stake in shares of Bristol Myers Squibb in the second quarter worth approximately $25,000. Physician Wealth Advisors Inc. lifted its stake in shares of Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 202 shares during the last quarter. Bayban bought a new stake in shares of Bristol Myers Squibb during the 4th quarter worth approximately $31,000. Finally, EQ Wealth Advisors LLC bought a new position in Bristol Myers Squibb in the 4th quarter valued at $32,000. Institutional investors own 76.41% of the company's stock.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Wall Street Zen upgraded Bristol Myers Squibb from a "buy" rating to a "strong-buy" rating in a research note on Saturday, June 27th. Guggenheim reissued a "buy" rating and set a $75.00 target price (up from $72.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Roth Capital began coverage on shares of Bristol Myers Squibb in a report on Wednesday, August 5th. They issued a "buy" rating and a $75.00 price target on the stock. Wells Fargo & Company set a $65.00 price objective on shares of Bristol Myers Squibb and gave the company an "equal weight" rating in a report on Friday, July 31st. Finally, Weiss Ratings raised shares of Bristol Myers Squibb from a "hold (c)" rating to a "hold (c+)" rating in a research report on Thursday, July 30th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Bristol Myers Squibb presently has a consensus rating of "Moderate Buy" and a consensus target price of $66.06.

• Why GRAIL Stock Could Be Biotech’s Next Big Breakout

Check Out Our Latest Stock Report on BMY

Bristol Myers Squibb Stock Performance

Shares of Bristol Myers Squibb stock opened at $66.07 on Wednesday. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89. The stock's fifty day moving average price is $59.94 and its 200-day moving average price is $59.14. The firm has a market cap of $134.97 billion, a P/E ratio of 14.55, a P/E/G ratio of 0.17 and a beta of 0.22. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $68.10.

• Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping analysts' consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The company had revenue of $12.97 billion during the quarter, compared to analyst estimates of $11.74 billion. During the same period in the prior year, the firm earned $1.46 earnings per share. The firm's revenue for the quarter was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, equities research analysts expect that Bristol Myers Squibb Company will post 6.95 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were given a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 3.8%. The ex-dividend date of this dividend was Thursday, July 2nd. Bristol Myers Squibb's dividend payout ratio is presently 55.51%.

Bristol Myers Squibb Profile

(Free Report)

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

Further Reading

• Five stocks we like better than Bristol Myers Squibb
• The AI Boom Is Turning This Cable Maker Into a Stock to Watch
• A Star Investor Just Trimmed Amazon—Here's What It means
• Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
• Home Depot Analysts See a Path to $375 and Beyond

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Bristol Myers Squibb Right Now?

Before you consider Bristol Myers Squibb, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol Myers Squibb wasn't on the list.

While Bristol Myers Squibb currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here